Liquidity & Technical
Liquidity & Technical
Capacity-constrained but tradable: $439M of stock can change hands inside five trading days at a normal 20% participation cap, which is enough for any single fund to hold a 5% position so long as total AUM is under roughly $8.8B. The tape itself reads neutral with a bearish tilt — price has clawed back to the 200-day moving average after a July 2025 death cross, but recent 5x-volume sessions have been distribution days, not accumulation, and three- and five-year relative performance has trailed broad equities.
Portfolio implementation verdict
5-Day Capacity (20% ADV, $M)
Largest Position Cleared in 5d (% mcap)
Supported AUM, 5% Weight ($B)
ADV 20d / Market Cap (%)
Technical Stance (-6 to +6)
Capacity-constrained, technically neutral. A fund up to ~$8.8B AUM can carry a 5% position at normal 20% ADV participation; above that, expect multi-week scale-in. Tape is not yet confirming a regime change — the July 2025 death cross has not been reversed, and the most recent high-volume sessions have been selloffs.
Price snapshot
Current Price ($)
YTD Return (%)
1Y Return (%)
52-Week Position (0–100)
Beta
Ten-year price with 50-day and 200-day moving averages
Most recent regime signal: death cross on 2025-07-22 (50-day crossed below 200-day). Last reversal — golden cross — was 2025-05-05. Whipsaw across 2025 reflects a stock without a clean trend.
Price closed at $281.98 versus the 200-day SMA at $281.80 — within 1% of the 200-day, effectively touching it from below. The 50-day ($274.45) still sits below the 200-day, so the regime remains a downtrend in transition: the recovery off the November 2025 low is real but the moving-average structure has not yet flipped back to bullish. Looking back ten years, today's price sits below the 2024 peak ($362) and well above the 2019 lows ($145) — mid-cycle, not a generational entry point.
Relative performance vs benchmark
Note. Broad-market and sector benchmark series were not available for this run. Absolute return context: CI is +14.6% over three years on a price basis (versus an S&P 500 typically up 30–40% in the same window). One-year absolute return is -15.5%. Relative strength is the weak link in the technical scorecard — the stock has lagged both equities broadly and managed-care peers since its 2024 peak.
Momentum — RSI(14) and MACD histogram, 18 months
RSI sits at 53.5 — squarely neutral, neither overbought nor oversold. Across 18 months, every push above 65 has failed inside two weeks (October 2025, June 2025, January 2025) and every plunge below 30 has been bought (December 2024, July 2025, November 2025). The MACD histogram just flipped negative this week after a constructive April bounce, signalling that the short-term momentum tailwind has stalled. Near-term momentum read: the bid is fading, but no oversold setup yet.
Volume, distribution days, and realized volatility
The conviction tell here is unambiguous: the three largest volume spikes in CI's modern history were all selloff days — the most recent (October 30, 2025) was a -17.4% gap-down on nearly 6× normal volume, indicating institutional liquidation rather than panic from retail. Day-to-day volume in the last six months has run 1.5–2.5M shares, with the 50-day average drifting sideways. This is not a tape being accumulated.
Realized 30-day volatility is 27.8% — between the 10-year p50 (25.2%) and p80 (33.3%) bands, so elevated but not stressed. The November 2025 spike to 65% (post-Q3 earnings) has fully unwound. For a beta-0.31 healthcare insurer, this is closer to the upper end of normal than the calm regime that prevailed in mid-2024.
Institutional liquidity panel
ADV 20d (M shares)
ADV 20d ($M traded)
ADV 60d (M shares)
ADV / Market Cap (%)
Annual Turnover (%)
Median 60-day intraday range is 1.26% — comfortably under the 2% threshold where impact costs become a material drag, so a multi-day VWAP execution should clear without unusual slippage. The practical takeaway: at normal 20% ADV participation, a fund can take on or trim up to about $439M (0.58% of float-market-cap) inside five trading days. That supports an 8.8B-AUM fund holding a clean 5% position. At conservative 10% participation, the bar drops by half — meaning anything beyond 0.5% of issuer market cap requires staged, multi-week building. CI is institutionally tradable for the typical mid-sized fund, but a fund larger than $10B cannot treat this as a top-five conviction position without becoming a meaningful share of daily volume.
Technical scorecard
Stance — 3-to-6 month horizon
Neutral with a bearish tilt. The two confirming signals are negative: high-volume days have been selloffs, and three- and five-year relative strength is poor against both equities and the managed-care peer set. The two offsetting signals are technical-mechanical: price has reclaimed the 200-day on the recovery off the November 2025 low, and 30-day realized volatility has compressed back into the normal band. The stock is close enough to its 200-day moving average that the next decisive move sets the regime. Bullish trigger: a sustained close above $300 — that clears the 100-day, takes price within striking distance of the 50-day reclaiming the 200-day, and would mark a clean reversal of the July 2025 death cross. Bearish trigger: a break below $267 — that takes price through the lower Bollinger band and the recent recovery shelf, opening a path back toward the 52-week low at $241.51 and likely a re-test of the October 2025 distribution low. Liquidity is not the primary constraint for funds under roughly $8.8B AUM at a 5% weight; for larger funds, the correct action is build slowly over multiple weeks rather than treating CI as a high-conviction position you can size into in days.